Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer

Acta Oncologica

Volumn 43, Issue 2, 2004, Pages 186-189

  Wist, Erik A ^a   Sommer, Hilde H ^a   Østenstad, Bjørn ^a   Risberg, Terje ^b   Bremnes, Yngve ^b   Mjaaland, Ingvild ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; TAXANE DERIVATIVE;

ABDOMINAL CANCER; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; ELECTROCORTICOGRAPHY; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; METASTASIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; RANDOMIZATION; SKIN METASTASIS; SURVIVAL RATE; THORAX WALL CANCER; TOXICITY; TREATMENT OUTCOME;

EID: 1842627763     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310023165     Document Type: Article

References (9)

1. Diasio RB. An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 2002; 20: 894-6.
2. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 998-1002.
3. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
4. Blum JL, Dieras V, Lo Russo PM, et al. Phase II study of capecitabine in taxane-pre-treated metastatic breast carcinoma patients. Cancer 2001; 92: 1759-68.
5. Reichardt P, von Mickwitz G, Luck HJ, et al. Capecetabine: the new standard in metastatic breast cancer failing anthracycline- and taxane-containing chemotherapy? Mature results of a large multicentre phase II trial. Eur J Cancer 2001; 37(Suppl. 6): (Abstr 699).
6. Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Phase II study of capecitabine (Xeloda®) in patients with advanced breast cancer (ABC) previously treated with anthracyclines and taxanes. Breast Cancer Res Treat 2001; 69: 285 (Abstr 435).
7. Cervantes G, Torrecillas L, Erazo A, et al. Capecitabine (XELODA) as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 121a (Abstr 469).
8. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
9. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-58.